{"url":"https://lda.senate.gov/api/v1/filings/fdff474b-78a8-4831-8cb5-9e014cb652fc/","filing_uuid":"fdff474b-78a8-4831-8cb5-9e014cb652fc","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2021,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/fdff474b-78a8-4831-8cb5-9e014cb652fc/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"John McManus","dt_posted":"2021-04-20T15:15:32.923000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"610 10th St NW","registrant_address_2":"#300","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":286096,"url":"https://lda.senate.gov/api/v1/registrants/286096/","house_registrant_id":36969,"name":"THE MCMANUS GROUP","description":"Consulting","address_1":"610 10th St. NW","address_2":"Suite 300","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JORDAN OPDAHL","contact_telephone":"+1 301-775-7048","dt_updated":"2026-07-20T15:27:02.288049-04:00"},"client":{"id":176479,"url":"https://lda.senate.gov/api/v1/clients/176479/","client_id":660,"name":"ALNYLAM PHARMACEUTICALS","general_description":"Biopharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-08-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P). Provisions related to vial wastage rebates in Part B. Implementation of Home Infusion Therapy Benefit.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":9573,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MCMANUS","suffix":null,"suffix_display":null},"covered_position":"Staff Director W&M Health Subcommittee; LA, Rep. Bill Thomas","new":false},{"lobbyist":{"id":73075,"prefix":null,"prefix_display":null,"first_name":"ALANNA","nickname":null,"middle_name":null,"last_name":"TEMME","suffix":null,"suffix_display":null},"covered_position":"LD, Rep. Jon Porter","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}